AMGN vs ZBIO
AMGN: Amgen is a leading biotechnology firm dedicated to developing innovative human therapeutics to address critical unmet needs in areas like oncology, inflammation, and cardiovascular disease. ZBIO: Clinical-stage immunology company developing obexelimab, a novel bifunctional monoclonal antibody targeting B cells for the treatment of autoimmune diseases.
Side-by-side fundamentals
| Metric | AMGN | ZBIO | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $439.33 | $32.29 | |
| Market cap as of 2026-08-24 | $237.5B | $2.1B | |
| P/E as of 2026-08-24 | 25.84 | n/a | |
| PEG as of 2026-08-24 | 5.48 | -0.10 | ZBIO lower |
| Net margin as of 2026-08-24 | +22.9% | -3777.4% | AMGN higher |
| Gross margin as of 2026-08-24 | +74.3% | n/a | |
| Operating margin as of 2026-08-24 | +30.3% | -3830.6% | AMGN higher |
| ROE as of 2026-08-24 | +89.3% | -167.7% | AMGN higher |
| ROA as of 2026-08-24 | +9.5% | -97.4% | AMGN higher |
| Debt / equity as of 2026-08-24 | 4.90 | 1.04 | ZBIO lower |
| Revenue growth (YoY) as of 2026-08-24 | +9.1% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +11.8% | -55.3% | AMGN higher |
| Dividend yield as of 2026-08-24 | +3.2% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-08-24 | 0.41 | 0.70 | |
| 1-year return as of 2026-08-21 close | +48.5% | +90.7% | ZBIO higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.